SGR-1505

P1, N=52, Recruiting, Schrödinger, Inc. | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026

Furthermore, a MALT1 inhibitor (JNJ-67856633) showed efficacy in mature B cell malignancies from phase 1 studies (ref 1, 2)...SGR-1505 administered as a single agent and in combination with the approved Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, demonstrates tumorostatic and regressive antitumor activity in ABC-DLBCL cell line-derived and patient-derived xenograft models...Subjects with symptomatic or active CNS involvement, and other conditions or laboratory findings placing them at increased risk to the use of an investigational drug are excluded. SGR-1505 is initially dose-escalated using an accelerated titration design in cohorts of 1-6 subjects, and at higher dose levels using a conventional 3+3 design.

P1, N=12, Not yet recruiting, Schrödinger, Inc.

P1, N=66, Not yet recruiting, Schrödinger, Inc

P1, N=52, Recruiting, Schrödinger, Inc. | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

SGR-1505 administered as a single agent and in combination with the approved Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, demonstrates tumorostatic and regressive antitumor activity in ABC- DLBCL cell line-derived xenograft and patient-derived xenograft models... Preclinical data suggest that SGR-1505 as a potent and well tolerated MALT1 inhibitor may provide therapeuticoptions for patients with select B-cell lymphomas. The overall risk-benefit of evaluating SGR-1505 in the clinical setting remains favorable.

P1, N=52, Recruiting, Schrödinger, Inc. | Initiation date: Oct 2022 --> Jun 2023

P1, N=52, Recruiting, Schrödinger, Inc. | Not yet recruiting --> Recruiting

P1, N=52, Not yet recruiting, Schrödinger, Inc.